Published in Am J Transplant on May 24, 2013
Report cards and quality: do center report cards predict quality or simply predict the next report card? Am J Transplant (2013) 1.07
Association between kidney transplant center performance and the survival benefit of transplantation versus dialysis. Clin J Am Soc Nephrol (2014) 0.94
Grading on a curve: the use and disadvantage of the standardized mortality ratio. Am J Transplant (2013) 0.75
Considerations of reliability and validity of transplant center report cards. Am J Transplant (2013) 0.75
The unintended consequences of publicly reporting quality information. JAMA (2005) 6.55
The risks of risk adjustment. JAMA (1997) 5.45
Use of public performance reports: a survey of patients undergoing cardiac surgery. JAMA (1998) 4.16
Racial profiling: the unintended consequences of coronary artery bypass graft report cards. Circulation (2005) 2.54
Calculating life years from transplant (LYFT): methods for kidney and kidney-pancreas candidates. Am J Transplant (2008) 2.39
Analytical methods and database design: implications for transplant researchers, 2005. Am J Transplant (2006) 2.14
American Society of Transplant Surgeons transplant center outcomes requirements--a threat to innovation. Am J Transplant (2009) 2.00
Comparison of "risk-adjusted" hospital outcomes. Circulation (2008) 1.78
Half of kidney transplant candidates who are older than 60 years now placed on the waiting list will die before receiving a deceased-donor transplant. Clin J Am Soc Nephrol (2009) 1.77
The association of community health indicators with outcomes for kidney transplant recipients in the United States. Arch Surg (2012) 1.53
The Maryland aggregate pathology index: a deceased donor kidney biopsy scoring system for predicting graft failure. Am J Transplant (2008) 1.48
Effect of comorbidity adjustment on CMS criteria for kidney transplant center performance. Am J Transplant (2009) 1.43
The association of center performance evaluations and kidney transplant volume in the United States. Am J Transplant (2013) 1.28
Transplant data: sources, collection and research considerations, 2004. Am J Transplant (2005) 1.22
Predictability of survival models for waiting list and transplant patients: calculating LYFT. Am J Transplant (2009) 1.22
The association of candidate mortality rates with kidney transplant outcomes and center performance evaluations. Transplantation (2008) 1.19
Significant alterations in reported clinical practice associated with increased oversight of organ transplant center performance. Prog Transplant (2010) 1.18
Report of a consensus conference on transplant program quality and surveillance. Am J Transplant (2012) 1.18
CMS oversight, OPOs and transplant centers and the law of unintended consequences. Clin Transplant (2010) 1.16
The pivotal impact of center characteristics on survival of candidates listed for deceased donor kidney transplantation. Med Care (2009) 1.15
Prediction models assessing transplant center performance: can a little knowledge be a dangerous thing? Am J Transplant (2006) 1.14
The aggressive phenotype: center-level patterns in the utilization of suboptimal kidneys. Am J Transplant (2011) 0.99
Do report cards influence hospital choice? The case of kidney transplantation. Inquiry (2006) 0.98
Accountability in health care--transplant community offers leadership. Am J Transplant (2009) 0.95
Outcome differences across transplant centers: comparison of two methods for public reporting. Clin J Am Soc Nephrol (2011) 0.94
Quality and Consumer Choice in Healthcare: Evidence from Kidney Transplantation. Top Econ Anal Policy (2006) 0.93
Improving organ transplantation in the United States--a regulatory perspective. Am J Transplant (2008) 0.92
Incorporating recipient choice in kidney transplantation. J Am Soc Nephrol (2004) 0.87
Cost of organ procurement and transplantation network data collection for a large transplant center. Am J Transplant (2003) 0.82
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Kidney transplantation under FK 506. JAMA (1990) 7.45
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Barriers to cadaveric renal transplantation among blacks, women, and the poor. JAMA (1998) 5.10
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Why hemodialysis patients fail to complete the transplantation process. Am J Kidney Dis (2001) 3.02
Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol (2001) 2.99
Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82
Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet (1997) 2.81
Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer (2006) 2.76
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
Determining the area under the ROC curve for a binary diagnostic test. Med Decis Making (2001) 2.54
Factors predicting recovery of erections after radical prostatectomy. J Urol (2000) 2.44
Risk factors for urinary incontinence after radical prostatectomy. J Urol (1996) 2.42
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (1995) 2.19
Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res (1997) 2.16
Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. Transplant Proc (1990) 2.15
FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. Transplantation (1990) 2.13
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol (1999) 2.00
Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant (2013) 1.99
Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res (1998) 1.95
Role of murein lipoprotein in morphogenesis of the bacterial division septum: phenotypic similarity of lkyD and lpo mutants. J Bacteriol (1978) 1.94
Effective control of hepatic bleeding with a novel collagen-based composite combined with autologous plasma: results of a randomized controlled trial. Arch Surg (2000) 1.89
Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant (2012) 1.88
Logistics and technique for combined hepatic-intestinal retrieval. Ann Surg (1992) 1.85
Outcome of preimplantation genetic diagnosis of translocations. Fertil Steril (2000) 1.78
Monitoring and treatment of intestinal allograft rejection in humans. Transplant Proc (1993) 1.78
Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer (2009) 1.77
Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc (1991) 1.75
Small intestinal transplantation in humans with or without the colon. Transplantation (1994) 1.74
Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker. Am J Transplant (2011) 1.71
Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc (1991) 1.69
EMG responses to maintain stance during multidirectional surface translations. J Neurophysiol (1998) 1.67
Strategies for transplantation of cadaveric kidneys with congenital fusion anomalies. J Urol (2001) 1.65
Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology (2001) 1.65
A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res (2000) 1.64
Association of metabolic syndrome with kidney function and histology in living kidney donors. Am J Transplant (2013) 1.63
The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc (1991) 1.60
PCR primers for human chromosomes: reagents for the rapid analysis of somatic cell hybrids. Genomics (1991) 1.58
New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc (1991) 1.56
Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant (2006) 1.55
Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol (2001) 1.55
Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol (1999) 1.54
Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant (2013) 1.54
Laparoscopic retroperitoneal live donor right nephrectomy for purposes of allotransplantation and autotransplantation. J Urol (2000) 1.52
A catalog of prostate cancer nomograms. J Urol (2001) 1.51
Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg (2001) 1.44
Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology (2000) 1.44
Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2001) 1.42
Intestinal transplantation at the University of Pittsburgh. Transplant Proc (1994) 1.42
Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology (1997) 1.41
A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc (1991) 1.40
Control of stance during lateral and anterior/posterior surface translations. IEEE Trans Rehabil Eng (1998) 1.39
Reduced employment in caregivers of frail elders: impact of ethnicity, patient clinical characteristics, and caregiver characteristics. J Gerontol A Biol Sci Med Sci (2001) 1.37
FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc (1991) 1.37
Abdominal multivisceral transplantation. Transplantation (1995) 1.37
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol (2000) 1.33
Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant (2000) 1.33
Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit (1995) 1.30
The association of center performance evaluations and kidney transplant volume in the United States. Am J Transplant (2013) 1.28
Effect of stance width on multidirectional postural responses. J Neurophysiol (2001) 1.28
The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Med Decis Making (1999) 1.28
Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol (1996) 1.26
Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol (1998) 1.26
Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol (1997) 1.24
Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol (1993) 1.23
Successful outcomes in pheochromocytoma surgery in the modern era. J Urol (1999) 1.23
The relationship between clinical assessments of nutritional status and adverse outcomes in older hospitalized medical patients. J Am Geriatr Soc (1999) 1.22
Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol (2001) 1.22
Postural orientation, equilibrium, and the spinal cord. Adv Neurol (1997) 1.21
Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2001) 1.21
Adaptation of the walking pattern to uphill walking in normal and spinal-cord injured subjects. Exp Brain Res (1999) 1.20
Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract (2004) 1.20
Weight support and balance during perturbed stance in the chronic spinal cat. J Neurophysiol (1999) 1.20
A critique of the decision analysis for clinically localized prostate cancer. J Urol (1994) 1.20
Impact of a clinical pathway for radical retropubic prostatectomy. Urology (1998) 1.20
Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation (1999) 1.19
Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg (1992) 1.18
Early death or retransplantation in adults after orthotopic liver transplantation. Can outcome be predicted? Transplantation (1994) 1.18
Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol (2000) 1.16
The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc (1991) 1.16
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol (2001) 1.15
A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. Clin Transplant (1994) 1.15
Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst (1997) 1.14
Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer (2001) 1.14
Cryptococcal meningitis: an analysis among 5,521 consecutive organ transplant recipients. Transpl Infect Dis (2002) 1.14
Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer (1998) 1.13
Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis (1992) 1.12